Literature DB >> 25060218

The impact of pyrvinium pamoate on colon cancer cell viability.

Armin Wiegering1, Friedrich-Wilhelm Uthe, Melanie Hüttenrauch, Bettina Mühling, Michael Linnebacher, Franziska Krummenast, Christoph-Thomas Germer, Andreas Thalheimer, Christoph Otto.   

Abstract

PURPOSE: The in vitro and in vivo effects of pyrvinium pamoate (PP), a newly identified WNT signaling inhibitor, were evaluated against colon cancer cell lines and primary colon cancer samples. EXPERIMENTAL
DESIGN: Antiproliferative activity of PP and its effects on protein and RNA levels of WNT targets were evaluated on adenomatous polyposis coli (APC (mut)) and β-catenin(mut) cell lines, one WNT(wt) colon cancer cell line, as well as six primary colon cancer samples with mutant APC in vitro. In addition, the effect of PP on the growth of liver metastasis was examined.
RESULTS: PP blocked colon cancer cell growth in vitro in a dose-dependent manner with great differences in the inhibitory concentration (IC(50)), ranging from 0.6 × 10(-6) to 65 × 10(-6) mol/L for colon cancer cells with mutations in WNT signaling. In addition, PP demonstrated a cytotoxic effect on primary colon cancer samples. A combined cytotoxic effect of PP with 5-fluorouracil (5-FU) was observed for two cell lines. PP decreased messenger RNA (mRNA) and protein levels of known WNT target genes as c-MYC and thereby led to the induction of p21. PP inhibited the migration of HCT116 colon cancer cells in vitro and decreased tumor growth in vivo after intraportal injection of HCT116 cells in nude mice.
CONCLUSIONS: PP displays promising anticancer activity against a broad panel of human colon cancer cell lines, as well as primary colon cancer samples. However, our findings do not demonstrate a predominant cytotoxic effect of PP on colon cancer cells with mutations in WNT signaling.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25060218     DOI: 10.1007/s00384-014-1975-y

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  29 in total

1.  [Direct complexometric calcium determination in serum with calcein as indicator].

Authors:  H LANGENDORF
Journal:  Klin Wochenschr       Date:  1958-09-01

2.  Noninvasive visualization of tumor growth in a human colorectal liver metastases xenograft model using bioluminescence in vivo imaging.

Authors:  Andreas Thalheimer; Doreen Korb; Lars Bönicke; Armin Wiegering; Bettina Mühling; Manuela Schneider; Silvia Koch; Simone S Riedel; Christoph Thomas Germer; Andreas Beilhack; Stephanie Brändlein; Christoph Otto
Journal:  J Surg Res       Date:  2013-03-30       Impact factor: 2.192

3.  Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α.

Authors:  Curtis A Thorne; Alison J Hanson; Judsen Schneider; Emilios Tahinci; Darren Orton; Christopher S Cselenyi; Kristin K Jernigan; Kelly C Meyers; Brian I Hang; Alex G Waterson; Kwangho Kim; Bruce Melancon; Victor P Ghidu; Gary A Sulikowski; Bonnie LaFleur; Adrian Salic; Laura A Lee; David M Miller; Ethan Lee
Journal:  Nat Chem Biol       Date:  2010-10-03       Impact factor: 15.040

4.  Pyrvinium pamoate does not activate protein kinase CK1, but promotes Akt/PKB down-regulation and GSK3 activation.

Authors:  Andrea Venerando; Cristina Girardi; Maria Ruzzene; Lorenzo A Pinna
Journal:  Biochem J       Date:  2013-05-15       Impact factor: 3.857

5.  Pyrvinium pamoate inhibits proliferation of myeloma/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3.

Authors:  Yasuo Harada; Isao Ishii; Kiyohiko Hatake; Tadashi Kasahara
Journal:  Cancer Lett       Date:  2011-12-27       Impact factor: 8.679

6.  The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis.

Authors:  Donald R Senger; Carole A Perruzzi; Michael Streit; Victor E Koteliansky; Antonin R de Fougerolles; Michael Detmar
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

Review 7.  Colorectal cancer.

Authors:  David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling
Journal:  Lancet       Date:  2010-03-20       Impact factor: 79.321

8.  Comprehensive molecular characterization of human colon and rectal cancer.

Authors: 
Journal:  Nature       Date:  2012-07-18       Impact factor: 49.962

9.  Pyrvinium targets autophagy addiction to promote cancer cell death.

Authors:  Longfei Deng; Yunlong Lei; Rui Liu; Jingyi Li; Kefei Yuan; Yi Li; Yi Chen; Yi Liu; You Lu; Carl K Edwards; Canhua Huang; Yuquan Wei
Journal:  Cell Death Dis       Date:  2013-05-02       Impact factor: 8.469

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  10 in total

1.  Androgen inhibits key atherosclerotic processes by directly activating ADTRP transcription.

Authors:  Chunyan Luo; Elisabeth Pook; Bo Tang; Weiyi Zhang; Sisi Li; Kirsten Leineweber; Shing-Hu Cheung; Qiuyun Chen; Martin Bechem; Jing-Shan Hu; Volker Laux; Qing Kenneth Wang
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-06-20       Impact factor: 5.187

Review 2.  Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28.

Authors:  Phuong N Le; Jessica D McDermott; Antonio Jimeno
Journal:  Pharmacol Ther       Date:  2014-08-27       Impact factor: 12.310

3.  Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer.

Authors:  Efrat Dotan; Dana B Cardin; Heinz-Josef Lenz; Wells Messersmith; Bert O'Neil; Steven J Cohen; Crystal S Denlinger; Safi Shahda; Igor Astsaturov; Ann M Kapoun; Rainer K Brachmann; Shailaja Uttamsingh; Robert J Stagg; Colin Weekes
Journal:  Clin Cancer Res       Date:  2020-07-21       Impact factor: 12.531

4.  Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.

Authors:  C Otto; S Schmidt; C Kastner; S Denk; J Kettler; N Müller; C T Germer; E Wolf; P Gallant; A Wiegering
Journal:  Neoplasia       Date:  2019-11-14       Impact factor: 5.715

5.  Identification of pyrvinium pamoate as an anti-tuberculosis agent in vitro and in vivo by SOSA approach amongst known drugs.

Authors:  Qing Guan; Lingjun Zhan; Zhi-Hao Liu; Qin Pan; Xu-Lin Chen; Zhen Xiao; Chuan Qin; Xiao-Lian Zhang
Journal:  Emerg Microbes Infect       Date:  2020-02-04       Impact factor: 7.163

Review 6.  Repositioning of Anthelmintic Drugs for the Treatment of Cancers of the Digestive System.

Authors:  Federica Laudisi; Martin Marônek; Antonio Di Grazia; Giovanni Monteleone; Carmine Stolfi
Journal:  Int J Mol Sci       Date:  2020-07-13       Impact factor: 5.923

7.  Pyrvinium pamoate inhibits cell proliferation through ROS-mediated AKT-dependent signaling pathway in colorectal cancer.

Authors:  Wenqian Zheng; Jinhui Hu; Yiming Lv; Bingjun Bai; Lina Shan; Kangke Chen; Sheng Dai; Hongbo Zhu
Journal:  Med Oncol       Date:  2021-02-08       Impact factor: 3.064

8.  Comparison of a histone deacetylase inhibitor plus exemestane with exemestane alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: A meta-analysis.

Authors:  Liang Xu; Weifan Jiang; Wenwei Li; Chungen Guo; Lihua Luo; Yufeng Gao; Yali Cao
Journal:  Exp Ther Med       Date:  2022-07-18       Impact factor: 2.751

Review 9.  A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers.

Authors:  Kamal Ahmed; Holly V Shaw; Alexey Koval; Vladimir L Katanaev
Journal:  Cancers (Basel)       Date:  2016-07-14       Impact factor: 6.639

10.  Targeting Mitochondria in Melanoma.

Authors:  Sepideh Aminzadeh-Gohari; Daniela D Weber; Luca Catalano; René G Feichtinger; Barbara Kofler; Roland Lang
Journal:  Biomolecules       Date:  2020-09-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.